

A VEGF-R2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

Stuart Emanuel, Robert H. Gruninger, Angel Fuentes-Pesquera, Peter J. Connolly, Jennifer A. Seamon, Susan Hazel, Rose Tominovich, Beth Hollister, Cheryl Napier, Michael R. D'Andrea, Michael Reuman, Gilles Bignan, Robert Tuman, Dana Johnson, David Moffatt, Mark Batchelor, Anne Foley, James O'Connell, Rodger Allen, Martin Perry, Linda Jolliffe and Steven A. Middleton.

Cancer Therapeutics Research [S.E., R.H.G., A. F.-P., P.J.C., J.A.S., M.R., G.B., L.J., S.A.M.] and Oncology Research [R.T., M.R.D., R.T., D.J.], Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey 08869; Institute of Medical and Veterinary Science, Adelaide, Australia 5007 [S.H.]; Piedmont Research Center, Morrisville, North Carolina 27560 [B.H., C.N.]; Celltech Research, Limited, Slough, United Kingdom [D.M., M.B., A.F., J.O'C., R.A., M.P.].

Running title: VEGF-R kinase inhibitor potentiates chemotherapeutic agents.

Corresponding author: Stuart Emanuel at Johnson & Johnson Pharmaceutical Research & Development, L.L.C.,
1000 Route 202, Raritan, New Jersey, 08869. Tel. 908-704-5815; FAX 908-704-4996; E-mail:
semanuel@prdus.jnj.com.

Number of text pages: 36

Number of tables: 6

Number of figures: 7

Number of references: 46

Number of words in Abstract: 249

Number of words in Introduction: 820 (744 without references)

Number of words in Discussion: 1384

The abbreviations used are: VEGF, vascular endothelial growth factor; VEGF-R2, VEGF receptor 2; PDGF-R β , platelet-derived growth factor receptor beta; EGF-R, epidermal growth factor receptor; FGF-R, fibroblast growth factor receptor; HASMC, human aortic smooth muscle cells; HUVEC, human umbilical vein vascular endothelial cells; PLC- γ , phospholipase-C-gamma; MEM, minimal essential medium; CDK, cyclin dependent kinase; HER2, human epidermal growth factor receptor 2; FGF-R2, fibroblast growth factor receptor 2; GSK3, glycogen synthase kinase 3 beta subunit; CAM, chorioallantoic membrane; D5W, 5% dextrose in water; PO, oral administration, QD, once a day, QOD, once every other day, BID, twice daily.

ABSTRACT

Inhibition of angiogenesis may have wide utility in the treatment of cancer, however, this approach alone will not cause tumor regression but may only slow the growth of solid tumors. The clinical potential of antiangiogenic agents might be increased by combining them with conventional chemotherapeutics. JNJ-17029259 represents a novel structural class of 5-cyanopyrimidines that are orally available, selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2) and other tyrosine kinases involved in angiogenesis such as the PDGF-R, FGF-R, VEGF-R1 and VEGF-R3, but have little activity on other kinase families. At nanomolar levels, JNJ-17029259 blocks VEGF-stimulated MAP kinase signaling, proliferation/migration and VEGF-R2 phosphorylation in human endothelial cells, inhibits the formation of vascular sprouting in the rat aortic ring model of angiogenesis, and interferes with the development of new veins and arteries in the chorioallantoic membrane assay. At higher concentrations of 1 - 3 μM , this compound shows antiproliferative activity on cells that may contribute to its antitumor effects. JNJ-17029259 delays the growth of a wide range of human tumor xenografts in nude mice when dosed orally as single agent therapy. Histological examination revealed that the tumors have evidence of reduced vascularity following treatment. In addition, JNJ-17029259 enhances the effects of the conventional chemotherapeutic drugs doxorubicin and paclitaxel in xenograft models when dosed orally in combination therapy. An orally available angiogenesis inhibitor that can be used in conjunction with standard chemotherapeutic agents to augment their activity may have therapeutic benefit in stopping the progression of cancer and preventing metastasis.

The vascular endothelial growth factor receptor-2 (VEGF-R2) mediates the process of angiogenesis by inducing the survival, proliferation and migration of endothelial cells (Millauer et al., 1993). Angiogenesis is prominent during embryonic development but in a normal adult occurs only as a result of injury or during endometrial turnover. However, several pathological conditions initiate the growth of new blood vessels including diabetic retinopathy, age-related macular degeneration, endometriosis, rheumatoid arthritis and the vascularization of primary and secondary tumors (Folkman, 1995). Specific inhibitors of VEGF-R2 activity might have potential therapeutic benefit in managing these conditions. The growth of solid tumors beyond the size of a few millimeters in diameter is dependent on the ability to recruit new blood vessels from the existing vascular network (Folkman, 1972).

Among the stimulators of neovascularization, the VEGF family [VEGF-A, VEGF-B, VEGF-C and VEGF-D] and their corresponding tyrosine kinase receptors [VEGF-R1 (Flt-1), VEGF-R2 (Flk-1; KDR) and VEGF-R3 (Flt-4)] play a central role in the angiogenic process (Ferrara, 1999). Expression of the VEGF receptors is restricted primarily to endothelial cells where the VEGF ligands exert mitogenic, chemotactic and permeability effects that are mediated through the VEGF receptor tyrosine kinases (Mustonen and Alitalio, 1995). Binding of VEGF-A or -B to VEGF-R1 or VEGF-A, -C or -D to VEGF-R2, or VEGF-C or -D to VEGF-R3 leads to receptor dimerization, tyrosine autophosphorylation, and signal transduction. In the case of VEGF-R2, stimulation by VEGF activates multiple signal transduction pathways including phosphorylation of phospholipase-C- γ (PLC- γ), MAP kinase, GAP and selected Src and Shc isoforms, leading to the formation of Shc-Grb2 and Nck complex formation (Waltenberger et al., 1994; Kroll and Waltenberger, 1997). Biological activities such as mitogenic and chemotactic responses of endothelial cells along with changes in endothelial cell morphology, increased permeability and membrane ruffling are principally mediated through VEGF-R2 activation of MAP kinase via the PLC- γ , protein kinase-C and raf-1 MEK pathways and by the p38 kinase in response to VEGF (Rosseau et al., 1997). In contrast, VEGF-R1 does not mediate a mitogenic response in endothelial cells or in transfected cells upon VEGF binding but can induce chemotactic activity in monocytes (Barleon et al., 1996). VEGF-R1 is phosphorylated after ligand binding but induces different signal transduction pathways from VEGF-R2 in transfected cells. The expression level of VEGF in tumor cells has been shown to correlate with tumor growth rate, vascular density and tumor metastasis (Takahashi et al., 1995). A variety of approaches to blocking VEGF action have been shown to inhibit tumor growth, including

neutralizing antibodies to the VEGF ligand (Kim et al., 1993) or the VEGF receptor (Witte et al., 1998), antagonistic VEGF variant proteins (Siemeister et al., 1998), soluble VEGF receptor proteins (Millauer et al., 1994), antisense constructs (Cheng et al., 1996), dominant negative mutants (Millauer et al., 1996), ribozymes (Ke et al., 1998) and transfection of tumor cells with inducible VEGF expression constructs (Benjamin et al., 1997). Targeting the tumor vasculature is an attractive point of therapeutic intervention as angiogenesis is required for expansion of all solid tumor types. The endothelial cell type is less likely to develop multi-drug resistance than genetically unstable cancer cells (Boehm et al., 1997) and, unlike some targeted therapeutic agents, efficacy is independent of the genetic profile of the tumor cell. Directing therapy at the endothelial network gives drugs direct access to the microvasculature target without the need to penetrate through the tumor mass. Bevacizumab (Avastin), a monoclonal antibody to VEGF that was recently approved by the FDA, has shown encouraging results in the clinic where it has demonstrated activity alone and in combination with conventional therapeutic regimens (Kabbinarar et al., 2003; Yang et al., 2003). Blockade of VEGF-R2 can prevent formation of new vessels but does not destroy existing vasculature, so this strategy may not induce regression of late-stage established tumors (Bergers et al., 2002). Combining antiangiogenic agents with standard therapies may provide greater therapeutic potential over single agent regimens (Morioka et al., 2003). Both antibodies and kinase inhibitors directed at the EGF-R have been shown to augment the activity of standard therapeutics (Ciardiello et al., 1999; Bruns et al., 2000), but there are few reports of VEGF-R2 kinase inhibitors able to enhance the activity of cytotoxic agents (Ciardiello et al., 2003). A variety of small molecule kinase inhibitors targeted at the VEGF-R2 have been developed or are being evaluated in clinical trials including compounds in the indolinone (Fong et al., 1999), quinazoline (Wedge et al., 2002) and phthalazine (Wood et al., 2000) structural classes. In this report we describe an orally bioavailable, small molecule inhibitor of the VEGF-R2 receptor kinase from a novel 5-cyanopyrimidine scaffold and characterize its pharmacological properties to inhibit VEGF-mediated signal transduction, prevent angiogenesis and inhibit solid tumor growth in human tumor xenograft models. We also show that administration of JNJ-17029259 enhances the antitumor activity of doxorubicin and paclitaxel in tumor xenograft models *in vivo* and this encourages further studies into the clinical benefits of combining VEGF-R2 kinase inhibitors with cytotoxic agents.

MATERIALS AND METHODS

Reagents. JNJ-17029259 (4-[4-(1-Amino-1-methylethyl)phenyl]-2-[4-(2-morpholin-4-yl)-

ethyl)phenylamino]pyrimidine-5-carbonitrile) (Fig. 1) was synthesized by Celltech Research, Ltd., and the Cancer Therapeutics Research team (J&J Pharmaceutical Research & Development, L.L.C.). All studies were carried out with the free base form of the compound. The VEGF-A (VEGF₁₆₅; R&D Systems, Minneapolis, MN) form of the ligand was used to stimulate HUVEC cells. Doxorubicin was obtained from Meiji Seika Kaisha (Japan) and paclitaxel from NaPro Biotherapeutics (Boulder, CO).

Cell Culture. HUVEC cells were obtained from Cascade Biologicals (Portland, OR) and maintained in EGM medium (Clonetics, San Diego, CA) containing low serum growth supplement. For VEGF-stimulated proliferation and migration assays, HUVECs were maintained in Medium 200 (Cascade Biologicals, Portland, OR). Human aortic smooth muscle cells (HASMC) were obtained from Cascade Biologicals (Portland, OR) and maintained in medium 231 containing smooth muscle growth supplement. MRC-5 normal lung fibroblasts, MS1 mouse transformed endothelial cells and all other cell lines were from the American Type Culture Collection (Manassas, VA). The following human tumor cell lines were used: HeLa (cervical adenocarcinoma), HCT116 (colon carcinoma), SK-OV-3 (ovarian adenocarcinoma), PC-3 (prostate adenocarcinoma), A375 (melanoma), A431 (epidermoid carcinoma), MX1 (breast carcinoma), A2780 (ovarian carcinoma), MV522 (lung carcinoma) and MDA-MB-231 (breast carcinoma). Cell culture reagents were obtained from Life Technologies, Inc. (Grand Island, NY). Cells were maintained at 37°C plus 5% CO₂ as exponentially growing monolayers in the following media supplemented with 10% FCS (Hyclone, Logan, UT) and 2 mM L-glutamine: HeLa and MDA-MB-231 in minimal essential medium (MEM) with 0.1 mM non-essential amino acids and 1 mM sodium pyruvate, HCT116 and SK-OV-3 in McCoys 5a, PC-3 in Hams F12K, MRC-5 in Eagles MEM and A375 in Dulbecco's modified Eagles medium with 4 mM L-glutamine and 1.5 g/L sodium bicarbonate.

VEGF Receptor Kinase Assays. Tyrosine kinase activity was measured in streptavidin coated 96-well scintillating microplates (NEN, Boston, MA) using an N-terminal HIS-tagged soluble rat VEGF-R2 construct expressed and purified from baculovirus. A biotinylated peptide substrate consisting of a fragment of PLC- γ was used as the phosphate acceptor and inhibition was measured by quantifying the amount of ³³P- γ -ATP incorporated into the immobilized peptide in the presence of various concentrations of test compound. VEGF-R2 enzyme was diluted in

50 mM Tris-Cl (pH 8), 10 mM MgCl₂, 0.1 mM Na₃VO₄, 1 mM DTT, 1% DMSO, 0.25 μM peptide substrate, 0.8 μCi per well ³³P-γ-ATP [2000-3000 Ci/mmol] and 5 μM ATP in the presence or absence of test compound and incubated at 30°C for 1 hour. The reaction was terminated by washing with PBS containing 100 mM EDTA and plates were counted in a scintillation counter. Linear regression analysis of the percent of inhibition by test compound was used to determine IC₅₀ values (GraphPad Prism 3, GraphPad Software, SanDiego, CA).

Selectivity Kinase Assays and Substrates. Assays for inhibition of additional kinases were performed as described for the VEGF-R2 with slight modifications to the assay buffer and different peptide substrates as appropriate for each enzyme. The following N-terminal biotinylated peptides were used: Biotin-AEPDYGALYEGRNPGFYVEANP-amide (VEGF-R2, PDGF-Rβ and HER2), Biotin-KTPKKAKKPKTPKKAKKL-amide (CDK1 and CDK2), Biotin-Poly(GT) 4:1 (Insulin receptor kinase, FGF-R2 and EGF-R), Biotin-GRTGRRNSI-amide (protein kinase A), Biotin-RFARKGSLRQKNV-amide (protein kinase C), Biotin-KRRRALS(phospho)VASLPGL-amide (casein kinase 1), Biotin-RREEETEEEE-amide (casein kinase 2), Biotin-KKALRRQETVDAL-amide (calmodulin dependent protein kinase 2), Biotin-KRREILSRRP(phospho)SYR-amide (glycogen synthase kinase-3), Biotin-APRTPGGRR-amide (MAP kinase ERK-2). The c-kit assay did not utilize a substrate and measured autophosphorylation activity as described for VEGF receptor autophosphorylation.

Definition and Source of Kinase Enzymes. VEGF-R2 is a fusion protein containing a polyhistidine tag at the N-terminus followed by amino acids 786-1343 of the rat VEGF-R2 kinase domain (GenBank Accession #U93306). Cyclin dependent kinase 1 (CDK1) was isolated from insect cells expressing both the human CDK1 catalytic subunit and its positive regulatory subunit cyclin B (New England Biolabs, Beverly, MA). CDK2 in complex with cyclin A is commercially available (Upstate Biotech, Lake Placid, NY). Insulin receptor kinase consists of residues 941-1313 of the cytoplasmic domain of the beta-subunit of the human insulin receptor (BIOMOL, Plymouth Meeting, PA). Protein kinase-A is the catalytic subunit of cAMP dependent protein kinase-A purified from bovine heart (Upstate Biotech, Lake Placid, NY). Protein kinase-C is the gamma or beta isoform of the human protein produced in insect cells (BIOMOL, Plymouth Meeting, PA). Casein Kinase 1 is a truncation at amino acid 318 of the C-terminal portion of the rat delta isoform produced in *E.coli* (New England Biolabs, Beverly, MA). Casein Kinase 2 includes the alpha and beta subunits of the human protein produced in *E.coli* (New England Biolabs,

Beverly, MA). Calmodulin-dependent protein kinase 2 is a truncated version of the alpha subunit of the rat protein produced in insect cells (New England Biolabs, Beverly, MA). Glycogen Synthase Kinase-3 (GSK3 β) is the beta isoform of the rabbit enzyme produced in *E.coli* (New England Biolabs, Beverly, MA). Mitogen activated protein (MAP) kinase is the rat ERK-2 isoform containing a polyhistidine tag at the N-terminus produced in *E.coli* and activated by phosphorylation with MEK1 prior to purification (BIOMOL, Plymouth Meeting, PA). The epidermal growth factor receptor (EGFR) is purified from human A431 cell membranes (Sigma, St. Louis, MO). c-kit consists of the intracellular domain of the human receptor with an N-terminal polyhistidine tag (PanVera, Madison, WI). The platelet derived growth factor receptor beta (PDGF-R β) is a fusion protein containing a polyhistidine tag at the N-terminus followed by nucleotides 1874-3507 of the human PDGF-R β subunit kinase domain (Accession #M21616). The human epidermal growth factor receptor-2 (HER2) construct contains a polyhistidine tag at the N-terminus followed by 24 additional amino acids and begins at amino acid 676 (Accession #M11730) followed by the remainder of the HER2 cytoplasmic domain.

In Vitro Autophosphorylation of VEGF Receptor. Autophosphorylation of VEGF receptor was determined as described above with the soluble rat VEGF-R2 construct as the only substrate. The VEGF-R2 enzyme was immobilized from the N-terminal HIS tag by dispensing the reaction mixture into the well of an NTA-nickel coated scintillating microplate (NEN, Boston, MA) and allowing the reaction to proceed at 30°C for 1 hour. The reaction was terminated by washing with PBS and plates were counted in a scintillation counter. Inhibition of the enzymatic activity of the VEGF-R2 was measured by observing a reduced amount of ³³P- γ -ATP incorporated into the immobilized enzyme.

Inhibition of Signal Transduction in HUVEC Cells. To measure the ability of compound to inhibit the activation of VEGF-mediated MAP kinase signaling in HUVEC cells, approximately 10⁷ cells were seeded and allowed to adhere overnight. Growth medium was removed and replaced with medium containing 0.1% fetal bovine serum and cells were incubated an additional 24 hours. Cells were then incubated with drug or DMSO vehicle alone for 16 hours at a final DMSO concentration of 1%. Following stimulation with 100 ng/ml human recombinant VEGF-A for 5 minutes, cells were lysed in HNTG [50 mM Hepes, 150 mM NaCl, 0.5% triton-X-100, 8% glycerol, 2 mM Na₃VO₄, 1.5 mM MgCl₂, 1mM EDTA containing the protease inhibitors AEBSF, aprotinin, leupeptin, bestatin,

pepstatin-A and E64] and total protein was quantified with the BCA protein assay (Pierce, Waltham, MA). The phosphorylation state of the MAP kinase protein ERK1/2 isoforms was detected by SDS-PAGE analysis of 20 micrograms of total protein and immunoblotting with antibodies for phospho-specific (Cell Signaling Technology, Beverly, MA) and total (Promega, Madison, WI) MAP kinase protein. To evaluate the effects of the compound on VEGF-R2 phosphorylation in endothelial cells, 3.5×10^4 HUVEC cells were plated in 48 well cell culture dishes in EGM medium supplemented with 10% FCS and cultured for 48 hours. Serial dilutions of drug in DMSO (or DMSO vehicle for controls) were added covering the concentration range of 100 μ M to 10 nM and cells were incubated 90 minutes at 37°C. Drug treated or vehicle treated cells were stimulated with 100 ng/ml of VEGF-A for 7 minutes and cells were lysed in HNTG. The extent of phosphorylation of the VEGF-R2 in cell lysates was determined in 96-well plates coated with a specific capture antibody followed by an antiphosphotyrosine detection antibody and measuring absorbance at OD₄₅₀. The maximum signal was obtained from control wells containing vehicle stimulated with VEGF after subtraction of the background from wells not stimulated with VEGF. Stimulation of cells with VEGF increased the phosphotyrosine levels of the VEGF-R2 by at least 7-fold. Linear regression analysis of the percent of inhibition by test compound was used to determine IC₅₀ values.

Inhibition of VEGF-stimulated HUVEC Proliferation and Migration. To evaluate inhibition of VEGF-stimulated proliferation, HUVEC cells were seeded into 24 well plates at 5×10^4 cells per well. Experimental compounds were tested at 0.001, 0.01, 0.1, 1, and 10 μ M. The negative control corresponded to basal medium alone (medium 200 + 0.5% BSA). The positive control and all experimental groups were treated with basal medium supplemented with VEGF (20 ng/ml) and all groups were set up in triplicate. After an incubation period of 72 hours at 37°C, cell monolayers were harvested and cells were counted. To evaluate inhibition of VEGF-stimulated migration, HUVEC cells were seeded into fibronectin coated transwells in a 24-well format. The effect of the experimental compounds on VEGF-induced migration was tested at 0.001, 0.01, 0.1, 1, and 10 μ M. The negative control corresponded to basal medium alone (medium 200 + 0.2% BSA). The positive control and all experimental groups were treated with basal medium supplemented with VEGF (10 ng/ml) added to the lower chamber of the wells and all groups were set up in triplicate. After a 4 hour incubation period at 37°C, cells on the top side of the transwell membrane were scraped with a cotton swab, and cells on the under side of the transwell membrane

(migrated cells) were stained with Calcein AM. Fluorescent images of migrated cells were obtained under 4X magnification using an Olympus 1X-70 microscope. Five fields were analyzed per transwell.

Cell Proliferation Assays. General antiproliferative activity of VEGF-R kinase inhibitors was assessed in monolayer cultures by ^{14}C -thymidine incorporation into cellular DNA. Briefly, 5×10^3 cells were plated into 96-well scintillating microplates (Cytostar-T, Amersham Pharmacia Biotech, Buckinghamshire, UK) in appropriate culture medium and allowed to adhere for 24 hours under standard culture conditions. Cells remained in logarithmic growth phase during the period of the assay and did not reach confluence. 24 hours after plating, test compound was added and cells were incubated for an additional 24 hours. Following this incubation, $0.2 \mu\text{Ci}/\text{well}$ ^{14}C -thymidine was added and allowed to incorporate into cellular DNA for 24 hours after which time the plate was washed with PBS and counted in a scintillation counter. Total time that cells were exposed to drug was 48 hours.

Rat Aortic Ring Assay. The *in vitro* rat aortic ring assay was performed according to the method of Nicosia and Antonetti (1990) and the degree of inhibition of vascular sprouting was quantified with an image analysis program as described (Nissanov et al., 1995). Briefly, thoracic aorta were freshly isolated from 1 to 2 month old Sprague Dawley rats and 1mm long sections were embedded in 1.5% agarose coated 6-well plates in gels of fibrin. Serum-free MCDB 131 media was added to the wells and the cultures were incubated at 37°C in 5% CO_2 . Explants generate branching microvessels over a 7 to 14 day period. Vehicle (DMSO) or test compound was added over a concentration range of 0.001 to $10.0 \mu\text{M}$ on day 0 and again together with fresh media on day 2 and day 5 of culture. Microvessel growth was quantified on day 8 of culture and expressed as microvessel area (pixels²). The percent inhibition of microvessel area of drug-treated rings compared to vehicle-treated control rings was calculated using the mean values for each treatment group. Statistical differences between experimental groups were analyzed by ANOVA and Dunnett's t-test, with a p-value of 0.05 or less considered statistically significant. Linear regression analysis of the percent of inhibition by test compound was used to determine IC_{50} values.

Early Chorioallantoic Membrane Assay. The early chorioallantoic membrane (CAM) assay is a modification of the classical chicken CAM assay and was performed as described (Hazel, 2003). In brief, fertilized chicken eggs

were incubated for 3 days at 39.5°C and embryos were cracked from the eggshell and placed in an incubation apparatus containing DMEM growth medium. On day 4, embryos were photographed at 5X magnification under a dissecting microscope, digital images were captured and the area of the CAM was measured with image analysis software. Embryos were divided into treatment groups and drug or vehicle was applied on 5-8 mm methylcellulose discs that were placed on top of the CAMs. After an incubation period of 18-24 hours, contrast agent dissolved in skim milk was injected into the CAM with a 30 gauge needle and images were captured at 5X and 63X magnification. Vein lengths, artery lengths and CAM areas were determined from the 5X image. Vein diameters were measured from images at the 63X magnification. Statistical analysis was performed using ANOVA followed by Student-Newman-Keuls method of multiple comparisons. Where data were not normally distributed, ANOVA on Ranks was performed.

Histological analysis of PC3 tumors. Tumors from a PC3 xenograft model were established to 0.15 (cm³) prior to initiation of dosing. The control group was treated with vehicle and the experimental group was treated for 30 days with 100 mg/kg of JNJ-17029259. Tissues were collected and fixed in PBS containing 10% buffered formalin and were routinely processed for paraffin embedding. Five µm sections were placed on microscopic slides for the progressive polychromatic hematoxylin and eosin stain, which stains red blood cells bright red (Sheehan and Hrapchak, 1980). Tumor sections showing no signs of necrosis, which approximately represented the center area of the tumor, were analyzed for red blood cell content per unit area using computer-assisted image analysis (Olympus BX-50, Sony 3CCD DKC-5000 camera, Image Pro, v. 4.1.0.9, Media Cybernetics, Phase III Imaging, Glen Mills, PA). Briefly, image analysis values were set to measure the brightly red-stained red blood cells in tissues, which were analyzed in a blinded fashion. Specifically, red blood cells were identified through the software to determine the total area occupied by red blood cells, which was obtained as a function of area density. These values were calibrated by comparing the negative control slides to the stained slides. As an additional control, all of the captured tissue images for the analysis were stored with identical photographic settings. Analysis was performed under low magnification using a 10X objective (150X final magnification). Three scanning areas per animal (n = 4/group) were selected from areas of the tumor that had obvious regions of red blood cells. Data was calculated as a percentage of the amount of red blood cell staining in the total tissue area (total area of positive pixels/total number

of pixels) and subjected to Student's t-test statistical analysis using SigmaStat (SPSS Inc., San Rafael, CA) and plotted using SigmaPlot (SPSS Inc., San Rafael, CA).

Tumor Xenograft Models. Female *nu/nu* mice (Harlan), 9-10 weeks of age, were fed *ad libitum* water and an irradiated standard rodent diet. Mice were housed in static microisolators on a 12-hour light cycle at 21 - 22°C and 40% - 60% humidity. All procedures complied with recommendations of the *Guide for Care and Use of Laboratory Animals* and followed AAALAC guidelines. Mice were implanted subcutaneously with 1 mm³ tumor fragments or 5 X 10⁶ cells in the right hind flank. Animals were pair matched on Day 1 when their tumors were in the 40 - 126 mg range. Estimated tumor weight was calculated using the formula: Tumor weight (mg) = (w² * l)/2; where w = width and l = length in mm. JNJ-17029259 was administered orally in 0.5% methylcellulose containing 0.1% polysorbate 80 in sterile water. Doxorubicin was prepared in saline and administered i.v. A stock solution of paclitaxel was prepared in 50% ethanol and 50% cremophor and diluted 10-fold into D5W prior to i.v. dosing. The tumor growth delay (TGD) method was followed where each animal was euthanized when its neoplasm reached a predetermined size. The predetermined "cut-off" tumor size varied for each cell line and was set at 2000 mg for A375, A431 and A2780, 1500 mg for MX1 and HCT116 and 1000 mg for PC3 and MV522. The mean tumor growth delay in days was calculated by subtracting the mean time to endpoint of the vehicle treated group from the mean time to endpoint of drug treated groups. The endpoint was the maximum tumor size permitted for each model. Compound dosing was carried out for 30 - 45 days on various schedules of administration as indicated in Table 5. Once dosing ceased, tumor measurements continued until all animals in each group reached the endpoint. Data was collected out to Day 58 - 65, depending on the model, for any animals remaining on study. Animals were weighed twice weekly during the study and mice were examined frequently for clinical signs of any adverse, drug-related side effects. All statistical analyses were conducted at p-level of 0.05 (two-tailed). Prism (GraphPad) version 3 was used for all statistical analysis and for graphic presentation.

RESULTS

Inhibition of VEGF-R2 Kinase Activity *In Vitro*. JNJ-17029259 (Fig. 1) represents a novel class of 5-cyanopyrimidine kinase inhibitors and inhibits the activity of the rat and the human VEGF-R2 kinase domain with similar potencies. IC_{50} values of 25 and 21 nM, respectively, were obtained for phosphorylation of the PLC- γ peptide in the rat or poly G:T substrate in the human assay. In these *in vitro* kinase assays, JNJ-17029259 exhibits potency superior to the comparator compounds SU-5416, ZD-6474 and PTK787 (Table 1). When substrate was omitted in an *in vitro* autophosphorylation assay, JNJ-17029259 inhibited autoactivation of the VEGF-R2 with similar potency to the substrate-based assays (IC_{50} of 16 ± 3 nM, data not shown), indicating that this compound acts directly on the VEGF-R2 to interfere with its activity and not through interaction with the substrates utilized in the kinase assay.

***In Vitro* Kinase Selectivity Profile.** To characterize the selectivity of inhibition, JNJ-17029259 was tested for activity against a representative panel of tyrosine and serine/threonine kinases. The general procedure used to assay for kinase activity was the same as that used in the primary VEGF-R2 screen except each assay used a different biotinylated peptide substrate and some buffer components varied slightly for each protein kinase. Known inhibitor compounds appropriate for the kinase being assayed were also included on each plate as internal controls. Among the kinase activities examined, JNJ-17029259 showed selectivity for inhibition of receptor tyrosine kinases involved in angiogenesis, with significant activity on the VEGF-R1, VEGF-R3 and FGF-R1 and some inhibition of the PDGF-R β , all of which have essential functions in neovascularization. ZD-6474 is a more potent inhibitor of the EGF-R than the VEGF-R2 and is about 10-fold less potent on the VEGF-R1 than the other compounds (Table 1 and 2).

Inhibition of Signal Transduction by JNJ-17029259 in HUVEC Cells. To determine if JNJ-17029259 is able to penetrate into cells and block VEGF-mediated signal transduction, HUVEC cells were treated for 16 hours with 1 or 10 μ M JNJ-17029259. Cells were then stimulated with VEGF and cell lysates were prepared. Lysates were examined by western blot with a phosphorylation state specific antibody to the ERK1/2 isoforms of MAP kinase, a key mediator of biological activity following VEGF stimulation (Waltenberger et al., 1994; Takahashi et al., 1999). The VEGF-induced activation of ERK1/2 phosphorylation in HUVEC cells was completely inhibited by treatment

with 1 or 10 μ M JNJ-17029259 (Figure 2) indicating that this compound effectively blocks signal transduction induced by the VEGF growth factor. In cells treated with vehicle only, VEGF stimulation resulted in phosphorylation of ERK1/2 protein (Figure 2). Blots were also probed with an antibody to total ERK1/2 to show the amount of protein present in each lane and the protein load was approximately equal for all treatment conditions. We next determined if treatment of HUVEC cells with JNJ-17029259 could block the VEGF-stimulated phosphorylation of the VEGF-R2. Cells were incubated for 90 minutes with drug or vehicle, stimulated with VEGF and lysates were evaluated for phosphotyrosine levels of the VEGF-R2 in a sandwich ELISA as described in Materials and Methods. As shown in Table 1, JNJ-17029259 inhibited tyrosine phosphorylation of the VEGF-R2 in HUVECs following stimulation with VEGF ligand with an IC_{50} value of 52 ± 14 nM. For comparison, reported IC_{50} values for the inhibition of VEGF-stimulated phosphorylation of the VEGF-R2 in HUVEC cells by SU-5416, ZD-6474 and PTK787 (Manley et al., 2002) are shown in Table 1. These VEGF-R2 inhibitors were assayed under conditions similar to those described here. The potency of JNJ-17029259 compares favorably with these VEGF-R2 kinase inhibitors and this shows that the compound is able to reach its intracellular target and prevent activation of the VEGF-R2 in endothelial cells.

Effects of JNJ-17029259 on VEGF-induced HUVEC Proliferation and Migration. The effect of JNJ-17029259 on VEGF-stimulated HUVEC cell proliferation was determined. While treatment of HUVEC cells with increasing concentrations of JNJ-17029259 showed a trend towards inhibition of VEGF-stimulated proliferation, this effect was not statistically significant due to the small window of proliferation induced by VEGF treatment. The group treated with 10 μ M JNJ-17029259 does not reflect inhibition of VEGF-stimulated proliferation but rather is likely due to toxicity of the compound, which occurs at this concentration, as growth was inhibited below the basal level seen in the absence of VEGF stimulation in the NO VEGF negative control group (Figure 3A). JNJ-17029259 prevented the VEGF-induced migration of HUVEC cells with inhibition of cell migration observed at all concentrations tested down to 1 nM and these results were statistically significant (Figure 3B). Some general toxicity was apparent at the highest concentration tested (10 μ M), but to a lesser degree in this assay than seen in the HUVEC proliferation assay due to the shorter 4-hour incubation period of the migration assay. Separate positive and negative controls were run for each compound evaluated.

Effects of JNJ-17029259 on Cell Proliferation. The antiproliferative activity of JNJ-17029259 was assessed with cell proliferation assays in various human cancer cell lines and on primary MRC-5 human lung fibroblasts, HASMC and HUVEC cells. These assays were intended to investigate the effect of the compound on cell growth that is unrelated to inhibition of the VEGF-R2. The IC_{50} for inhibition of cell proliferation by test compound was measured by incorporation of ^{14}C -thymidine into cellular DNA. JNJ-17029259 exhibited an antiproliferative effect on cell growth with IC_{50} values in the 1 to 3 micromolar range depending on the cell type (Table 3). Antiangiogenic effects occur at much lower concentrations of compound and are separated from the growth inhibitory effects observed in this assay. This is illustrated by the difference in the IC_{50} values for inhibition of HUVEC growth in basal medium (2.57 μ M) compared to the inhibition of VEGF-stimulated growth (0.1 μ M) calculated from the VEGF-stimulated HUVEC proliferation assay (Table 3 and Figure 3A). To estimate the non-VEGF specific effects of JNJ-17029259 on mouse endothelial cells the antiproliferative activity towards the MS1 cell line was evaluated. MS1 is a transformed mouse endothelial line that maintains the phenotypical characteristics of endothelial cells including expression of Flk-1 (VEGF-R2), Factor VIII related antigen and uptake of acetylated LDL (Arbiser et al., 1997). Growth of the transformed mouse endothelial cell line MS1 was inhibited in the same concentration range as the other cell types examined (Table 3).

Vascular Sprouting Assay. Compounds were evaluated for the ability to affect the formation of new vessel outgrowth from segments of rat aortic rings embedded in a fibrin gel. JNJ-17029259 suppressed the growth of new vascular processes in this *in vitro* model of angiogenesis in a dose dependent fashion with an IC_{50} of 50 ± 34 nM (Table 1). PTK787 has also been reported to inhibit the formation of new vessels in this assay (Wood et al., 2000) with an IC_{50} value of 675 nM under similar assay conditions except that capillary outgrowth was measured after day 6 as opposed to day 8 (Table 1).

JNJ-17029259 treatment in the CAM assay. Treatment with JNJ-17029259 resulted in reductions in vein and artery length and vein diameter of more than 50% at 20 nM and higher doses (Table 4, Figure 4). In the CAMs treated with 50 nM compound, 4 of 6 had no remaining blood flow. Total vein length decreased with an IC_{50} of 15.8 nM but was only inhibited a maximum of 30-35% at 20 to 50 nM compound. Total artery lengths were reduced with an IC_{50} of 17.8 nM and showed more of a dose response at higher concentrations of 20 nM to 50 nM JNJ-17029259

reaching a maximum inhibition of 11.7% at 50 nM. CAM growth was reduced to 57% of control in the 50 nM compound group, but this did not reach statistical significance. Vein diameters were significantly reduced in all of the groups treated with 20 nM or higher JNJ-17029259. Examples of CAMs treated with JNJ-17029259 are shown in Figure 4. At 20 nM compound, there is a large area of hemorrhage in the CAM and dilated vessel skeletons can be seen at the higher magnification. No blood flow remains in the CAM treated with 50 nM compound and there are only indistinct vessel remnants seen at the higher magnification.

Inhibition of Human Tumor Xenograft Growth. The anti-tumor activity of JNJ-17029259 was evaluated in several human tumor xenograft models in nude mice. Compound was formulated in 0.5% methylcellulose containing 0.1% Tween-80 and administered PO. Prior to initiating treatment, tumors were implanted and allowed to establish growth for 7 to 14 days. Results of these studies are summarized in Table 5 for the various tumor types. The A375 melanoma cell line was selected because it represents a highly vascular and fast growing tumor type and has been reported to express VEGF and the VEGF receptor KDR (Liu et al., 1995). In this model, statistically significant efficacy was obtained with daily doses of 100 and 50 mg/kg JNJ-17029259 while there was not significant delay of tumor growth at the 25 or 12.5 mg/kg doses (Table 5). For this tumor type, twice daily dosing did not seem to have any advantage over once daily dosing with the same cumulative dose when inhibition of tumor size or tumor growth delay was calculated. A375 tumor growth delay results for the 50 and 100 mg/kg once a day dose groups are shown in Figure 5A, showing tumor size, and Figure 5B, showing the time to endpoint obtained for these same groups. Time to endpoint refers to percent of mice remaining on study and includes only those animals that had tumors smaller than the predetermined cutoff size of 2000 mg. Animals were removed from the study when their tumors reached the cutoff size and recorded as a death due to cancer.

The PC3 cell line was selected for study as an androgen independent prostate carcinoma because these tumors as a class can be difficult to treat with standard therapies. Enhanced neovascularization of the PC3 xenografts may also be driven by VEGF secreted by these cells (Ravindranath et al., 2001). JNJ-17029259 slowed the growth of the PC3 tumor in a dose-dependent manner, however, the tumor growth inhibition was less than that seen in the A375 model, although still statistically significant at the 100 and 125 mg/kg doses (Table 5). In the A431 epidermoid carcinoma and MX1 breast carcinoma models, optimum efficacy was achieved from an intermittent dosing schedule of 125

mg/kg daily for four days followed by 3 days of no dosing. This dosing scheme was carried out for 40 days and resulted in a 61% inhibition of A431 tumor growth, which was not statistically significant, and a 55% inhibition of MX1 tumor growth which was significant (Table 5). The 50 mg/kg twice a day schedule also significantly delayed growth in the A431 tumor model. Other dosing schedules provided some inhibition of A431 and MX1 tumor growth but the activity was not significant for these models. The A2780 cell type was extremely fast growing with all the control animals reaching the study endpoint within 14 days. JNJ-17029259 administered alone did not produce a significant delay of tumor growth in this model. Significant inhibition was obtained following daily treatment with 100 mg/kg JNJ-17029259 in the MV522 lung carcinoma model and inhibition was seen at 50 mg/kg but the activity in this group was not statistically significant ($P = 0.06$) (Table 5). Treatment with 10 mg/kg JNJ-17029259 was not sufficient to inhibit HCT116 colon carcinoma growth; however, at 100 mg/kg there was significant inhibition of tumor growth compared to vehicle treated animals (Table 5).

Because non-cytotoxic agents will most likely be administered in combination with conventional chemotherapeutics, JNJ-17029259 was evaluated in A431 and MX1 xenograft models dosed alone and in combination with doxorubicin. In these studies, doxorubicin was administered i.v. at 3 mg/kg on a QD X 5 schedule. When dosed alone at 125 mg/kg in the A431 model or 100 mg/kg in the MX1 model, JNJ-17029259 demonstrated a non-significant inhibition of tumor growth with both of these tumor types (Table 6). When dosed in combination with doxorubicin, JNJ-17029259 enhanced the activity of this agent against the A431 and MX1 tumor types (Figure 6A, 6B and Table 6). The activity obtained with the combination of the two drugs showed significant inhibition of tumor growth that appeared to be additive with no increase in toxicity when 100 mg/kg of JNJ-17029259 was combined with 3 mg/kg of doxorubicin in the MX-1 study. When a higher dose of JNJ-17029259 was administered in conjunction with doxorubicin in the A431 study, there was an increase in treatment related deaths observed over the course of the study, with 5 of 8 animals lost by day 51 after 40 days of dosing with JNJ-17029259 at 125 mg/kg on a 4on/3off schedule combined with one cycle of doxorubicin administered for 5 consecutive days. JNJ-17029259 was also evaluated when dosed in combination with paclitaxel in A2780 ovarian tumor xenografts. The A2780 ovarian cell line is the only cell type examined not reported to express VEGF or its receptor. This tumor type was extremely fast growing with all untreated and vehicle treated animals reaching the maximum tumor size within 14 days (Figure 6C). When dosed alone, JNJ-17029259 produced no significant inhibition of tumor growth with 100

mg/kg daily dosing (Table 6). However, when JNJ-17029259 was administered in combination with paclitaxel, there was an enhanced inhibition of tumor growth which was significant (Figure 6 and Table 6). The combination of daily dosing with JNJ-17029259 at 100 mg/kg, and one cycle of paclitaxel administered QOD X 5 (every other day for a total of 5 doses) at 30 mg/kg, was well tolerated with no apparent toxicity and 3 out of 6 animals experienced a complete regression having no tumor present upon completion of the study. For all studies described, groups receiving daily doses of 100 mg/kg JNJ-17029259 alone appeared healthy and experienced an increase in mean body weight over the course of the treatment. Animals receiving paclitaxel or doxorubicin alone did not lose more than 5% of their body weight following treatment with these standard agents and body weight increased once treatment ceased. Animals receiving JNJ-17029259 plus doxorubicin or paclitaxel experienced a maximum mean body weight loss that did not exceed 16% for any combination but, once chemotherapeutic treatment ended, progressively gained the weight back and exhibited a net increase in weight at study end. No treatment related deaths occurred in any of the combination studies with chemotherapeutic agents when JNJ-17029259 was dosed at 100 mg/kg.

Histological effects of JNJ-17029259 in PC3 xenografts. Analysis of PC3 prostate carcinoma cells grown as xenografts in nude mice showed that there was a significant reduction in the area of red blood cell staining in animals treated once a day for 30 days with 100 mg/kg of JNJ-17029259 compared to animals treated with vehicle alone. While this is not a direct measure of vascularity, it is evidence of reduced blood supply in treated tumors.

DISCUSSION

This report describes a novel, orally available angiogenesis inhibitor that targets the VEGF-R2 tyrosine kinase. JNJ-17029259 is a potent inhibitor of VEGF-R2 mediated phosphorylation of a peptide fragment of PLC- γ 1. PLC- γ 1 is an essential component of the signal transduction from the activated VEGF-R2 mediating endothelial cell calcium flux, proliferation and differentiation (Meyer et al., 2003). The peptide substrate contains amino acids 771 and 783 that are functionally important tyrosine residues in the PLC- γ 1 protein. Phosphorylation of PLC- γ 1 on tyrosine 783 has been shown to be critical for signaling following PDGF and EGF stimulation (Kim et al., 1991) and this residue is also important for the downstream functions of the FGF and nerve growth factor receptor tyrosine kinases (Rhee, 2001). A direct effect on the activation of the VEGF-R2 is demonstrated by the ability of the compound to interfere with VEGF-stimulated phosphorylation of the VEGF-R2 in HUVEC cells with similar potency to that measured in the substrate based kinase assay. JNJ-17029259 possesses superior potency to the comparator compounds SU-5416, ZD-6474 and PTK787 against the human VEGF-R2 in substrate based kinase assays. Experiments to elucidate the mechanism of inhibition of JNJ-17029259 showed that the IC₅₀ value increased in proportion to the concentration of ATP in the assay consistent with an ATP competitive mode of action (data not shown). Kinase inhibitor profiling reveals that JNJ-17029259 has good selectivity for the target VEGF-R2 and also inhibits other kinases involved in neovascularization. Inhibition of unrelated kinases such as EGF-R may result in effects not related to angiogenesis that may be undesirable, however, activity on the FGF-R and PDGF-R β that are expressed on endothelial cells and involved in many of the same processes mediated through the VEGF-R2 (Compagni et al., 2000) could contribute to anti-angiogenic action. JNJ-17029259, ZD-6474 and PTK787 have activity against PDGF-R β , a receptor that can stimulate the mitogenesis and assembly of smooth muscle cells and pericytes into new vessels in conjunction with endothelial cells (Grosskreutz et al., 1999). Inhibition of the VEGF-R1 and VEGF-R3 receptors by JNJ-17029259, which are closely related and in the same family of receptor tyrosine kinases as the VEGF-R2, could confer therapeutic advantages as they are implicated in pathological angiogenesis (Hiratsuka et al., 2001; White et al., 2002).

Treatment of HUVEC cells showed that JNJ-17029259 has the capacity to reach its target in endothelial cells, prevent the autophosphorylation of the VEGF-R2 and block the VEGF-mediated processes of proliferation and migration that are critical for new vessel formation. At the highest concentration assayed (10 μ M) JNJ-17029259

exhibited some toxicity in the VEGF-stimulated HUVEC proliferation assay after a 72 hour treatment with drug. When tested *in vitro* in cell proliferation assays, JNJ-17029259 exhibits some general antiproliferative effects on human cancer cell lines and normal cell types that may be unrelated to inhibition of the VEGF-R2. In the non-VEGF-stimulated HUVEC cell proliferation assay, the IC₅₀ for inhibition of cell growth was 2.57 μM following a 48 hour exposure. The growth inhibitory effect on the MS1 mouse endothelial cell line was in the same range as for HUVEC human endothelial cells. JNJ-17029259 showed similar potency for slowing the growth of transformed cell lines or normal human cell types which did not seem to correlate with their expression of the VEGF-R2. However, JNJ-17029259 was 25-fold more potent for inhibition of VEGF-stimulated HUVEC proliferation where the IC₅₀ was around 0.1 μM. In an *in vitro* model of vascular sprouting, the compound was able to effectively disrupt angiogenesis as demonstrated by its inhibition of vascular outgrowth in the rat aortic ring assay with an IC₅₀ of 50 nM. The inhibition of neovascularization from rat aortic rings is not likely due to an antiproliferative effect on endothelial cells as the IC₅₀ value for this effect is well below the concentration required to interfere with HUVEC cell growth measured *in vitro*. Treatment with JNJ-17029259 also resulted in a dramatic inhibition of vascular formation in the CAM assay. Vein growth, artery growth and vein diameter were equally reduced and produced very similar IC₅₀ values of 15.8 nM, 16.9 nM and 17.6 nM, respectively. Various growth factors are implicated in the regulation of angiogenesis in the CAM such as bFGF; however, JNJ-17029259 is relatively inactive on the FGF-R2 so its effects in the CAM assay are most likely attributed to interference with VEGF-R, FGF-R1 or PDGF-R mediated processes. Although this compound clearly has antiangiogenic effects at lower concentrations, it also demonstrates antiproliferative effects on cancer cell lines when present at micromolar levels and may be delaying tumor growth in xenograft models by other mechanisms unrelated to its antiangiogenic properties. In fact, plasma levels of 2 - 6 μM are achieved under the 100 mg/kg daily dosing schedule used in the *in vivo* models (data not shown) and these levels are in the range where JNJ-17029259 exhibits antiproliferative activity towards cell lines in culture. In PC3 tumor xenografts there was evidence that treatment with JNJ-17029259 was able to reduce the density of red blood cells present in the tumors indicating that both antiangiogenic and antiproliferative mechanisms may be contributing to the antitumor activity of this compound.

JNJ-17029259 inhibited tumor xenograft growth after once a day oral dosing in a wide range of human cancer cell types. Delay of tumor growth was obtained with over 50% reduction in mean tumor size in several models

including A375, PC3, A431, MX1 and MV522, but tumor regression was not observed. Several of these cell types, such as A375 and PC3, are reported to express both VEGF and the VEGF-R2 and may therefore be stimulating angiogenesis in the mouse xenografts by both autocrine and paracrine mechanisms. The A375 cell line has been shown to respond to VEGF with increased proliferation (Liu et al., 1995). A431 cells secrete VEGF in monolayer cultures and are dependent on it for angiogenesis and growth *in vivo* (Viloria-Petit et al., 1991). The expression of VEGF by HCT116 cells is critical for their capacity to form tumors in nude mice (Okada et al., 1998) and VEGF production increases under hypoxic conditions in the MX1 cell line (Schmitt et al., 1992). JNJ-17029259 was efficacious under several schedules with 50 and 100 mg/kg once a day being the most frequently utilized regimens. When administered at 100 mg/kg on a daily basis JNJ-17029259 was well tolerated in all of the *in vivo* models with no reduction of body weight and no treatment related deaths occurring following 30 - 45 days of treatment. Doses below 50 mg/kg produced very minimal antitumor effects while doses as high as 125 mg/kg resulted in improved activity; however, prolonged daily dosing at this level could only be tolerated for about 30 days after which time treatment related deaths began to occur. This could be avoided by administering compound at the same high dose but on an intermittent dosing schedule of 4 days dosing followed by 3 days rest.

As VEGF-R2 kinase inhibitors are likely to be administered in conjunction with standard therapies, the ability of JNJ-17029259 to enhance the activity of two chemotherapeutic drugs was evaluated. At the 100 mg/kg dose, the compound was well tolerated when combined with doxorubicin or paclitaxel in MX1 or A2780 models, respectively, and was able to augment the effects obtained with either agent administered alone. Using the 125 mg/kg intermittent schedule, combination with doxorubicin in the A431 model increased the toxicity observed with higher doses of the compound indicating that the optimum dose must be determined for each agent to be administered in the combination. Blocking cancer progression by more than one mechanism simultaneously may be an attractive therapeutic approach with the potential for greater effectiveness over either agent alone (Morioka et al., 2003).

We have described a novel orally available angiogenesis inhibitor able to block VEGF-mediated signaling and inhibit vessel growth both *in vitro* and *in vivo*. JNJ-17029259 is a potent inhibitor of several of the receptor tyrosine kinases with roles in angiogenesis including VEGF-R1, -R2 and -R3 as well as FGF-R1 and PDGF-R β and likely

interferes with the process of vessel formation at multiple levels. This compound exhibits activity at delaying the growth of a variety of solid tumor types when dosed alone and is able to augment the activity of conventional chemotherapeutic agents when administered in combination therapy. JNJ-17029259 may also have utility for additional indications in which aberrant vascularization is involved, such as diabetic retinopathy and rheumatoid arthritis.

REFERENCES

- Arbiser, JL, Moses, MA, Fernandez, CA, Ghiso, N, Cao, Y, Klauber, N, Frank, D, Brownlee, M, Flynn, E, Parangi, S, Byers, HR and Folkman, J (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. *Proc Natl Acad Sci USA* 94:861–866.
- Barleon, B, Sozzani, S, Zhou, D, Weich, HA, Mantovani, A and Marme, D (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* 87:3336-3343.
- Benjamin, LE, and Keshet, E (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. *Proc Natl Acad Sci USA* 94:8761–8766.
- Bergers, G. and Hanahan, D (2002) Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. *Cold Spring Harbour Symposia on Quantitative Biology, Volume LXVII*:293-300.
- Boehm, T, Folkman, J, Browder, T and O'Reilly, MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. *Nature* 390:404-407.
- Bruns, CJ, Solorzano, CC, Harbison, MT, Ozawa, S, Tsan, R, Fan, D, Abbruzzese, J, Traxler, P, Buchdunger, E, Radinsky, R and Fidler, IJ (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. *Can Res* 60:2926-2935.
- Cheng, S-Y, Huang, H-JS, Nagane, M, Ji, X-D, Wang, D, Shih, CC-Y, Arap, W, Huang, C-M, and Cavenee, W K (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. *Proc Natl Acad Sci USA* 93:8502–8507.
- Ciardello, F, Bianco, R, Damiano, V, De Lorenzo, S, Pepe, S, De Placido, S, Fan, Z, Mendelsohn, J, Bianco, AR and Tortora, G (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. *Clin Can Res* 5:909-916.
- Ciardello, F, Caputo, R, Damiano, V, Caputo, R, Troiani, T, Vitagliano, D, Carlomagno, F, Veneziani, BM, Fontanini, G, Bianco, AR and Tortora, G (2003) Antitumor effects of ZD6474, a small molecule vascular

endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. *Clin Can Res* 9:1546-1556.

Compagni, A, Wilgenbus, P, Impagnatiello, M-A, Cotton, M and Christofori, G (2000) Fibroblast growth factors are required for efficient tumor angiogenesis. *Cancer Res* 60:7163-7169.

Ferrara, N. (1999) Molecular and biological properties of vascular endothelial growth factor. *J Mol Med* 77:527-543.

Folkman, J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. *Ann Surg* 175:409-416.

Folkman, J (1995) Clinical implications of research on angiogenesis. *N Engl J Med* 333:1757-1763.

Fong, TAT, Shawver, LK, Tang, C, App, H, Powell, TJ, Kim, YH, Schreck, R, Wang, X, Risau, W, Ullrich, A, Hirth, KP, and McMahon, G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. *Cancer Res* 59:99-106.

Grosskreutz, CL, Anand-Apte, B, Duplaa, C, Quinn, TP, Terman, B, Zetter, B and D'Amore, PA (1999) Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. *Microvascular Res* 58:128-136.

Hazel, S (2003) A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances. *J Lab Clin Med* 141:217-228.

Hiratsuka, S, Maru, Y, Okada, A, Seiki, M, Noda, T and Shibuya, M (2001) Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. *Cancer Res* 61:1207-1213.

Kabbinavar, F, Hurwitz, HI, Fehrenbacher, L, Meropol, NJ, Novotny, WF, Lieberman, G, Griffing, S and Bergsland, E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Onc* 21:60-65.

Ke, LD, Fueyo, J, Chen, X, Steck, PA, Shi, Y-X, Im, A-A, and Yung, WKA (1998) A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. *Int J Oncol* 12:1391-1396.

Kim, H-K, Kim, J-W, Zilberstein, A, Margolis, B, Kim, J-G, Schlessinger, J and Rhee, S-G (1991) PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. *Cell* 65:435-441.

- Kim, KJ, Bing, L, Winer, J, Armanini, M, Gillett, N, Philips, HS and Ferrera, N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. *Nature* 362:841-844.
- Kroll, J and Waltenberger, J (1997) The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. *J Biol Chem* 272:32521-32527.
- Liu, B, Earl, HM, Baban, D, Shoaibi, M, Fabra, A, Kerr, DJ and Seymour, LW (1995) Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. *Biochem Biophys Res Commun* 217:721-727.
- Manley, PW, Furet, P, Bold, G, Bruggen, J, Mestan, J, Meyer, T, Schnell, CR and Wood, J (2002) Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. *J Med Chem* 45:5687-5693.
- Meyer, RD, Latz, C and Rahimi, N (2003) Recruitment and activation of phospholipase C γ 1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. *J Biol Chem* 278:16347-16355.
- Millauer, B, Wizigmann-Voos, S, Schnurch, H, Martinez, R, Moller, NP, Risau, W and Ullrich, A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. *Cell* 72:835-846.
- Millauer, B, Shawver, LK, Plate, KH, Risau, W and Ullrich, A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1. *Nature* 367:576-579.
- Millauer, B., Longhi, MP, Plate, KH, Shawver, LK, Risau, W, Ullrich, A, and Strawn, LM (1996) Dominant-negative inhibition of Flk-1 suppresses the growth of many tumour types in vivo. *Cancer Res* 56: 1615–1620.
- Morioka, H, Weissbach, L, Vogel, T, Nielsen, GP, Faircloth, GT, Shao, L and Hornicek, FJ (2003) Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. *Clin Cancer Res* 9:1211-1217.
- Mustonen T and Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. *J Cell Biol* 129:895-898.
- Nicosia, RF and Antonetti, A (1990) Growth of microvessels in serum free matrix culture of rat aorta. *Lab Invest* 63:115-122.
- Nissanov, J, Tuman, RW, Gruver, LM and Fortunato, JM (1995) Automatic vessel segmentation and quantitation of the rat aortic ring assay of angiogenesis. *Lab Invest* 73:734-739.
- Okada, F, Rak, J, St. Croix, B, Lieubeau, B, Kaya, M, Roncari, L, Shirasawa, S, Sasazuki, T and Kerbel, RS (1998) Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth

factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal cells. *Proc Natl Acad Sci USA* 95:3609-3614.

Ravindranath, N, Wion, D, Brachet, P and Djakiew, D (2001) Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. *J Andrology* 22:432-443.

Rhee, S-G (2001) Regulation of phosphoinositide-specific phospholipase C. *Ann Rev Biochem* 70:281-312.

Rousseau, S, Houle, F, Landry, J and Huot, J (1997) p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. *Oncogene* 15:2169-2177.

Schmitt, O, Schubert, C, Feyerabend, T, Hellwig-Burgel, T, Weiss, C and Kuhnel, W (2002) Preferential topography of proteins regulating vascularization and apoptosis in a MX1 xenotransplant after treatment with hypoxia, hyperthermia, ifosamide, and irradiation. *Am J Clin Oncol* 25:325-336.

Sheehan, DC and Hrapchak, BB (1980) Theory and practice of histotechnology, 2nd edition. pp 143-144, Battelle Press, Columbus, Ohio.

Siemeister, G, Schirner, M, Reusch, P, Barleon, B, Marme, D and Martiny-Baron, G (1998) An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. *Proc Natl Acad Sci USA* 95:4625-4629.

Takahashi, Y, Kitadai, Y, Bucana, CD, Cleary, KR and Ellis, L (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. *Cancer Res* 55:3964-3968.

Takahashi, T, Ueno, H and Shibuya, M (1999) VEGF activates protein kinase C-dependent, but ras-independent raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. *Oncogene* 18:2221-2230.

Viloria-Petit, A, Crombet, T, Jothy, S, Hicklin, D, Bohlen, P, Schlaeppli, JM, Rak, J and Kerbel, RS. (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. *Cancer Res* 61:5090-5101.

Waltenberger, J, Claesson-Welsh, L, Siegbahn, A, Shibuya, M and Heldin, CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. *J Biol Chem* 269:26988-26995.

Wedge, SR, Ogilvie, DJ, Dukes, M, Kendrew, J, Chester, R, Jackson, JA, Boffey, SJ, Valentine, PJ, Curwen, JO, Musgrove, HL, Graham, GA, Hughes, GD, Thomas, AP, Stokes, ESE, Curry, B, Richmond, GHP, Wadsworth, PF,

Bigley, AL and Hennequin, LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. *Cancer Res* 62:4645-4655.

White, JD, Hewett, PW, Kosuge, D, McCulloch, T, Enholm, E, Carmichael, J and Murray, JC (2002) Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. *Cancer Res* 62:1669-1675.

Witte, L, Hicklin, DJ, Zhu, Z, Pytowski, B, Kotanides, H, Rockwell, P, and Bohlen, P (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. *Cancer Metastasis Rev* 17:155-161.

Wood, JM, Bold, G, Buchdunger, E, Cozens, R, Ferrari, S, Frei, J, Hofmann, F, Mestan, J, Mett, H, O'Reilly, T, Persohn, E, Rosel, J, Schnell, C, Stover, D, Theuer, A, Towbin, H, Wenger, F, Woods-Cook, K, Menrad, A, Siemeister, G, Schirner, M, Thierauch, K-H, Schneider, MR, Dreves, J, Martiny-Baron, G, Totzke, F and Marme, D (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. *Cancer Res* 60:2178-2189.

Yang, JC, Haworth, L, Sherry, RM, Hwu, P, Schwartzentruber, DJ, Topalian, SL, Steinberg, SM, Chen, HX and Rosenberg, SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *New Engl J Med* 349:427-434.

FIGURE LEGENDS

Figure 1. The chemical structure of JNJ-17029259.

Figure 2. Inhibition of VEGF-dependent phosphorylation of ERK1/2 in HUVECs by JNJ-17029259. Serum starved HUVECs were either untreated or treated with 1 or 10 μ M JNJ-17029259 for 16 hours. Cells were stimulated with 20 ng/ml of VEGF and cell lysates were subjected to western blot analysis to detect phosphorylated ERK1/2 (phospho-ERK 1/2) or total ERK1/2 (total ERK1/2). Lane 1 cells were not treated with drug and not stimulated with VEGF and show the basal level of phosphorylation after being serum starved for 16 hours. Lane 2 cells were not treated with drug but were stimulated with VEGF for 5 minutes to induce phosphorylation of ERK1/2. Cells in lanes 3 and 4 were treated with 1 and 10 μ M of JNJ-17029259, respectively, and show inhibition of ERK1/2 phosphorylation following drug treatment. Representative data is shown.

Figure 3. Effect of JNJ-17029259 on VEGF-stimulated HUVEC proliferation and migration. A, Inhibition of proliferation. Controls were either unstimulated (NO VEGF) or stimulated (20 ng/ml VEGF) with VEGF-A and allowed to grow for 72 hours. Ability of the compound to inhibit cell proliferation at concentrations from 1 nM to 10 μ M was determined. The basal level of growth observed in the absence of VEGF (NO VEGF group) is indicated by the dotted line. Inhibition of cell growth below the level of the NO VEGF control group indicates toxicity. Cell number was determined from direct cell counts. All groups were set up in triplicate and the data presented are means; *bars*, SE. B, Inhibition of migration. Controls were either unstimulated (NO VEGF) or stimulated (20 ng/ml VEGF) with VEGF-A and allowed to migrate for 4 hours. Ability of the compound to inhibit cell migration at concentrations from 1 nM to 10 μ M was evaluated. After an incubation period of 4 hours at 37°C, migrated cells were harvested and stained with Calcein AM. Fluorescent images of migrated cells were obtained under 4X magnification using an Olympus 1X-70 microscope. Five fields were analyzed per transwell. All groups were set up with n = 10 and the data presented are means; *bars*, SE. Statistical significance was evaluated by comparing the NO VEGF negative control or the drug treated groups to the VEGF induced positive control group using a two tailed Students t test. *, P < 0.05, **, P < 0.01, ***, P < 0.001.

Figure 4. Effects of treatment with vehicle or JNJ-17029259 in day 5 chicken CAMs. Treatment was initiated on day 4 and completed on day 5. Skim milk plus contrast agent was injected into the CAM to help visualize vessels.

Control CAMs were treated with vehicle only. At 20 nM JNJ-17029259 there is a large area of hemorrhage in the CAM at 5X and dilated vessel skeletons can be seen at the higher magnification of 63X. No blood flow remains in the CAM treated with 50 nM JNJ-17029259, and there are only indistinct vessel remnants even at the higher magnification.

Figure 5. Inhibition of A375 melanoma xenograft growth by JNJ-17029259. Experimental procedures are described in Materials and Methods. Briefly, tumor fragments were implanted *s.c.* (subcutaneously) into female nude mice and allowed to establish to a size of 40-126 mg at which time they were pair matched into groups; treatment was initiated on Day 1. Drug was formulated in 0.5% methylcellulose and administered orally once a day for 45 days. Mice were treated with vehicle (■), 50 mg/kg (○), or 100 mg/kg (□) JNJ-17029259. A, Tumor size was measured every three days. Values are means; bars, SE; n = 6. B, Survival is indicated as percent of animals remaining on study because mice bearing tumors that reached a predetermined cutoff size of 2000 mg were removed from the experiment so that tumors never exceeded 10% of body weight.

Figure 6. Vascular density in PC3 tumor xenografts. PC3 tumors (n = 4) were allowed to establish to a size of 0.15 (cm³) prior to initiation of treatment. Tumors were collected from vehicle treated (solid bar) or animals treated with 100 mg/kg JNJ-17029259 once each day for 30 days (open bar) and fixed in 10% buffered formalin. Histological sections were prepared and the red blood cells were stained brightly red using a H&E staining method to quantify the percentage of red blood cells per unit area. A significant reduction in the red blood cells per unit area was apparent following treatment with JNJ-17029259 in this tumor type. Data represent the mean ± SE of three fields (totaling ~ 11 mm²) analyzed for each sample. *p < 0.05 by two-tailed Student's t-test.

Figure 7. Effect of JNJ-17029259 on the growth of human tumor xenografts when dosed alone and in combination with paclitaxel or doxorubicin. JNJ-17029259 was administered orally in 0.5% methylcellulose containing 0.1% Tween-80. A, In the A431 model, JNJ-17029259 was dosed at 125 mg/kg on a 4 days on/3 days off schedule alone (○) or in combination with doxorubicin (□). B, In the MX1 model, JNJ-17029259 was dosed at 100 mg/kg/day alone (○) or in combination with doxorubicin (□). Doxorubicin was administered i.v. at 3 mg/kg/day for 5 days in both the A431 and MX1 models (dashed line in A and B). Vehicle treated animals (■) followed the same schedule

as JNJ-17029259. C, In the A2780 xenograft model, JNJ-17029259 was dosed at 100 mg/kg/day alone (○) or in combination with paclitaxel (□). Paclitaxel was administered at 30 mg/kg/day i.v. every other day for 10 days (dashed line in C). Tumor xenografts were established *s.c.* in the right hind flank of athymic mice and allowed to establish to 63-256 mg prior to initiation of treatment. In the A431 and MX1 models the activity of JNJ-17029259 administered alone was comparable to that obtained with doxorubicin alone. When JNJ-17029259 was dosed in combination with doxorubicin the activity was at least additive. In the A2780 model, JNJ-17029259 had a modest effect when dosed alone but enhanced the activity of paclitaxel when the two agents were dosed in combination. Data points represent means for 8 mice in all treatment groups and 10 mice in vehicle control groups. Bars, SE.

Table 1. *In vitro* activity of JNJ-17029259 and other VEGF-R2 kinase inhibitors

COMPOUND	Rat VEGF-R2	Human VEGF-R2	VEGF-R2	Rat aortic ring assay
	kinase activity ^a	kinase activity	phosphorylation in	IC ₅₀ (nM)
	IC ₅₀ (nM)	IC ₅₀ (nM)	HUVEC cells ^b	
			IC ₅₀ (nM)	
JNJ-17029259	25 ± 6	21 ± 0.6	52 ± 14	50 ± 34
SU-5416	---	220 ^c	884 ^c	---
ZD-6474	---	40 ^d	2,673 ^c	---
PTK787	---	42 ^c	16 ^c	675 ^e

^aInhibition of kinase activity was determined *in vitro* with rat or human recombinant enzymes. Data represent the mean (± SE) of at least 4 separate experiments.

^bVEGF-stimulated phosphotyrosine content of the VEGF-R2 was evaluated in HUVEC cells. Data represent the mean (± SE) of 4 separate experiments.

^cManley et al., 2002, ^dWedge et al., 2002, ^eWood et al., 2000.

Table 2. *In vitro* Selectivity of JNJ-17029259 and other VEGF-R2 kinase inhibitors. IC₅₀ (μM)

Kinase	JNJ-17029259	SU-5416	ZD-6474	PTK787
VEGF-R1	0.090 ± 0.009	0.043 ^a	0.90 ^a	0.077 ^c
VEGF-R3	0.012 ± 0.003	0.050 ^a	0.233 ^a	0.195 ^a
Tie2	1.95 ± 0.07	>10 ^a	0.567 ^a	>10 ^c
PDGF-Rβ	0.27 ± 0.09	2.22 ^a	0.477 ^a	0.580 ^c
FGF-R1	0.10 ± 0.02	>10 ^a	2.31 ^a	>10 ^c
FGF-R2	0.172 ± 0.004	---	---	---
FLT3	0.23 ± 0.05	---	---	---
c-kit	>100	0.660 ^a	0.343 ^a	0.730 ^c
CDK1:Cyclin B	4.80 ± 0.41	>10 ^a	>10 ^a	>10 ^c
EGF-R	>100	>10 ^a	0.016 ^a	>10 ^c
HER2	2.09 ± 0.57	---	>20 ^b	---
Protein kinase-A	>100	---	---	---
Protein kinase-Cγ	28.3 ± 2.88	---	---	---
Protein kinase-Cβ2	>100	---	---	---
Casein kinase-1	36.76 ± 0.88	---	---	---
Casein kinase-2	>100	---	---	---
Calmodulin kinase-2	24.52 ± 1.97	---	---	---
GSK3β	1.31 ± 0.1	---	---	---
ERK2 (MAPK)	>100	---	---	---
Insulin-R kinaseβ	>100	---	---	---

^aManley et al., 2002, ^bWedge et al., 2002, ^cWood et al., 2000.

Table 3. *In vitro* antiproliferative activity of JNJ-17029259.

Cell line	IC ₅₀ (μM)
HeLa	2.12 ± 0.31
HCT-116	2.74 ± 0.25
SK-OV-3	1.43 ± 0.18
PC3	1.84 ± 0.22
A375	1.28 ± 0.04
MDA-MB-231	2.77 ± 0.73

Normal cell type	IC ₅₀ (μM)
MRC-5	3.43 ± 0.67
HASMC	3.68 ± 0.40
MS1	3.74 ± 0.07
HUVEC non VEGF-stimulated	2.57 ± 0.47
HUVEC VEGF-stimulated	0.1 ^a

^aestimated from data in figure 3 (n=3).

Table 4. Quantitative measurements of CAM growth from Day 4-5, vessel lengths and vein diameter in the early CAM assay.

Dose (nM)	CAM growth	Vein length	Artery length	Vein diameter
JNJ-17029259	(%)	(%)	(%)	(%)
DMSO Only	100.0 ± 0.0	100.0 ± 0.0	100.0 ± 0.0	100.0 ± 0.0
5	103.5 ± 20.1	97.8 ± 13.8	101.7 ± 25.7	107.7 ± 25.1
10	97.4 ± 9.7	126.2 ± 15.9	97.3 ± 24.4	108.8 ± 13.1
20	80.1 ± 16.1	29.5 ± 13.7 ^a	30.2 ± 12.2 ^a	34.4 ± 10.6 ^a
30	67.9 ± 13.0	34.6 ± 25.4 ^a	16.1 ± 6.3 ^a	47.9 ± 16.0 ^a
40	79.2 ± 14.2	33.3 ± 18.8 ^a	28.8 ± 15.9 ^a	30.5 ± 14.8 ^a
50	56.7 ± 11.2	32.2 ± 22.4 ^a	11.7 ± 8.2 ^a	26.4 ± 18.5 ^a
<i>IC₅₀ value (nM)</i>	----	15.8 nM	17.6 nM	16.9 nM

^ap<0.05 vs DMSO using ANOVA on Ranks followed by a Student-Newman-Keuls method of multiple comparisons.

Table 5. *In vivo* activity of JNJ-17029259 in human tumor xenograft models

Tumor type	Schedule and dose (PO) ^a	% tumor growth inhibition ^b (P value ^c)	Mean tumor growth delay ^d (days)
A375 melanoma	100 mpk, QD X 45	65 (P = 0.002)	26.7 ± 7.2
	50 mpk, QD X 45	62 (P = 0.005)	13.5 ± 3.1
	50 mpk, BID X 45	70 (P = 0.007)	23.7 ± 3.2
	25 mpk, BID X 45	34 (P = 0.1)	12.2 ± 4
	12.5 mpk, BID X 45	15 (P = 0.52)	2.4 ± 3.4
PC3 prostate carcinoma	125 mpk, QD X 40	56 (P = 0.01)	2.3 ± 4
	100 mpk, QD X 40	38 (P = 0.004)	8.1 ± 3
	50 mpk, BID X 40	28 (P = 0.16)	4.4 ± 3.5
A431 epidermoid carcinoma	125 mpk, 4on/3off QD X 40	61 (P = 0.08)	21.3 ± 4.8
	100 mpk, QD X 40	48 (P = 0.07)	16.6 ± 4.2
	50 mpk, BID X 40	58 (P = 0.05)	8.8 ± 3.1
MX1 breast carcinoma	125 mpk, 4on/3off QD X 40	55 (P = 0.004)	13.2 ± 4.2
	100 mpk, QD X 40	41 (P = 0.11)	13.5 ± 4.8
	50 mpk, BID X 40	30 (P = 0.15)	9.2 ± 3.8
A2780 ovarian carcinoma	100 mpk, QD X 30	6.3 (P = 0.06)	1.9 ± 1
MV522 lung carcinoma	100 mpk, QD X 30	54 (P = 0.02)	9.1 ± 6.8
	50 mpk, QD X 30	51 (P = 0.06)	2 ± 6.7
HCT116 colon carcinoma	100 mpk, QD X 30	45 (P = 0.04)	13.8 ± 4.4
	10 mpk, QD X 30	12 (P = 0.14)	2.2 ± 2.5

^aAll dosing was PO with JNJ-17029259 formulated in 0.5% methylcellulose plus 0.5% Tween-80, QD-once a day, BID-twice a day, 4on/3off-4days of dosing followed by 3 days of holiday, QOD-every other day.

^bT/C% The percentage of tumor growth inhibition was calculated as the difference between the change in control and drug treated tumor volumes (T/C) on the last day that all animals were alive in both treatment and control groups.

^cStatistical significance was evaluated by comparing the the mean tumor size of vehicle treated groups to drug treated groups using a two tailed Students t test.

^dThe tumor growth delay in days was calculated by subtracting the mean time to endpoint of the vehicle treated group from the mean time to endpoint of treated groups. The endpoint was the maximum tumor size permitted for each model as described in Methods.

Table 6. *In vivo* activity of JNJ-17029259 in human tumor xenograft models
dosed in combination with doxorubicin or paclitaxel.


Tumor type	JNJ-17029259 schedule and dose (PO)	Second agent schedule and dose (IV)	% tumor growth inhibition ^a (P value ^b)	Mean tumor growth delay ^c (days)
A2780 ovarian carcinoma	None	paclitaxel 30 mpk, QOD X 5	57 (P = 0.019)	12.4 ± 1.1
	100 mpk, QD X 30	None	6 (P = 0.06)	1.9 ± 1.
	100 mpk, QD X 30	paclitaxel 30 mpk, QOD X 5	98 (P = 0.019)	31.3 ± 3.1
A431 epidermoid carcinoma	None	doxorubicin 3 mpk, QD X 5	37 (P = 0.006)	11.8 ± 5.1
	125 mpk, 4on/3off QD X 40	None	61 (P = 0.078)	21.3 ± 4.8
	125 mpk, 4on/3off QD X 40	doxorubicin 3 mpk, QD X 5	91 (P = 0.09)	ND ^d
MX1 breast carcinoma	None	doxorubicin 3 mpk, QD X 5	48 (P = 0.03)	15.2 ± 4.6
	100 mpk, QD X 40	None	41 (P = 0.11)	13.5 ± 4.8
	100 mpk, QD X 40	doxorubicin 3 mpk, QD X 5	96 (P = 0.01)	37 ± 2.5

^aThe percentage of tumor growth inhibition was calculated as described in Table 5.

^bStatistical significance was evaluated by comparing the mean tumor size of vehicle treated groups to drug treated groups using a two tailed Students t test.

^cThe tumor growth delay in days was calculated as described in the legend of Table 5. ND, not calculated

^dThis group experienced one case of partial regression and two cases of progressive disease along with 5 treatment related deaths.



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

VEGF-A



JNJ-17029259 (μM)



Phospho-ERK1/2 \rightarrow

Total-ERK1/2 \rightarrow

- + + +

0 0 1 10








Control




20 nM

50 nM

5X




63X





A

A375 Tumor Growth Delay

**B**


A375 Time to Endpoint






A


A431
Dosed with doxorubicin

**B**

MX1
Dosed with doxorubicin

**C**

A2780
Dosed with paclitaxel



■ Vehicle control

--- Standard agent alone

○ JNJ-17029259 alone

□ JNJ-17029259 plus standard agent